Compare IFN & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IFN | CRVS |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.5M | 634.0M |
| IPO Year | N/A | 2016 |
| Metric | IFN | CRVS |
|---|---|---|
| Price | $13.70 | $8.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | 135.2K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 8.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.40 | $2.54 |
| 52 Week High | $21.25 | $9.60 |
| Indicator | IFN | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 26.06 | 51.32 |
| Support Level | $13.75 | $8.31 |
| Resistance Level | $13.97 | $9.60 |
| Average True Range (ATR) | 0.22 | 0.54 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 14.43 | 26.75 |
India Fund Inc is an asset management company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing in the equity securities of Indian companies. The company's portfolio is a non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities, and others. Geographically, all the business activity functions through the market of the United States.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).